Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC plus regorafenib versus regorafenib alone as second-line treatment for advanced hepatocellular carcinoma
ChiCTR2300073075Phase 3Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jul 2023
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of regorafenib, oxaliplatin, folinic acid and fluorouracil in hepatocellular carcinoma (HCC) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: median overall survival. Started Jul 2023; status: recruiting.
02
Drugs
regorafeniboxaliplatinfolinic acidfluorouracil
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2300073075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073075.